The Evolving Landscape of Psoriasis Treatment
Abstract
The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Although mild disease can be treated with topical agents, for patients with moderate to severe disease, concurrent therapy with oral systemic agents, biologics, and/ or phototherapy needs to be considered. In some instances, clinicians may need to combine medications to provide patients with rapid relief of symptoms.
Semin Cutan Med Surg 37(supp2):S39-S43
© 2018 published by Frontline Medical Communications
Keywords
Biologics; phototherapy; psoriasis pathophysiology; systemic oral therapy; topical therapy
When researchers discovered in 1979 that the immunosuppressant cyclosporine successfully cleared psoriatic plaques, the scientific community began to consider psoriasis not “just a skin disease.”1,2 The cause of this chronic, multisystemic disease is dysregulation of the immune system.1 Approximately 3.2% of the American population has some form of psoriasis. Psoriasis vulgaris, the most common form of plaque psoriasis, affects 80% of people with psoriasis.1,3
New Treatment Paradigms in Psoriasis: Understanding and Incorporating Recent and Emerging Trends
This journal supplement is intended for dermatologists, residents, internists, primary care practitioners, registered nurses, nurse practitioners, and physi- cian assistants who treat patients with psoriasis.
Supported by an educational grant from:
Ortho Dermatologics
Activity Information
EXPIRED
Original Release Date: March 2018
Expiration Date: April 30, 2019
Estimated Time to Complete Activity: 2.0 hours
EXPIRED
Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.The online post-test and evaluation can be accessed at https://tinyurl.com/Psoriasis2018.
Inquiries about CME accreditation may be directed to the University of Louisville Office of Continuing Medical Education & Professional Development (CME & PD) at cmepd@louisville.edu or 502-852-5329.
Faculty
![]() | M. Alan Menter, MD, Chair |
![]() | April W. Armstrong, MD, MPH |
![]() | Kenneth B. Gordon, MD |
![]() | Jashin J. Wu, MD |
CME/CE Accreditation Statements
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.
The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education.
Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.8 contact hours of pharmacotherapy credit for Advance Practice Nurses.
Educational Needs
Psoriasis—a chronic, inflammatory, immune-system disease that affects approximately 8 million Americans—is often underdiagnosed. Many clinicians do not approach psoriasis as a systemic, immune-mediated disease with multiple comorbidities, including obesity, metabolic syndrome, cardiovascular disease, and psoriatic arthritis. Even though half of patients with psoriasis complain of arthritic pain, for example, more than two-thirds of dermatologists lack confidence in screening for arthritic comorbidities. Clinicians also frequently fail to screen patients with psoriasis for cardiovascular risk factors, in part because they are unaware that the presence of psoriasis is associated with poor CV outcomes.
Psoriasis is often undertreated. One recent survey found that two-thirds of patients with psoriasis reported being dissatisfied with their treatment; many discontinue treatment due to a lack of efficacy or because of adverse effects. Many clinicians fail to select a therapeutic option that addresses the needs of individual patients, and many neglect the importance of counseling patients adequately about the optimal use of medications or about what to expect from treatment. Complicating the situation is the fact that many clinicians do not adopt a treat-to-target strategy that establishes clear therapeutic goals based on treatment severity (including addressing quality-of-life issues) and that calls for adjusting the regimen as needed.
Clinicians would benefit from education that describes the growing armamentarium of available agents for the treatment of psoriasis, explains the importance of identifying and managing common comorbidities of psoriasis, and presents current data on designing and deploying a treat-to-target strategy, including the use of topical agents and biologics, alone or in combination.
Learning Objectives
By reading and studying this supplement, participants should be better able to:
- Explain the etiology and pathophysiology of psoriasis and its common comorbidities
- Diagnoseandtreatpatientswithpsoriasisusingtreat-to-targetguidelines
- Selectappropriatebiologictherapiesforpatientswithpsoriasis
Disclosure Declarations
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.
April W. Armstrong, MD, MPH, Consultant: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Modernizing Medicine, Novartis Pharmaceuticals Corporation, Regeneron, Sanofi. Speakers Bureau: AbbVie Inc., Eli Lilly and Company, Janssen Biotech, Inc.
Kenneth B. Gordon, MD, Consultant: AbbVie Inc., Amgen Inc., Almirall, S.A., Boehringer Ingelheim, Bristol Myers-Squibb Company, Celgene Corporation, Dermira,Inc.,Eli Lilly and Company, LEO Pharma Inc.,Novartis Pharmaceuticals Corporation, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc. Investigator: AbbVie Inc., Boehringer Ingelheim, Celgene Corporation, Novartis Pharmaceuticals Corporation.
M. Alan Menter, MD, Advisory Board: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Boehringer Ingelheim, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC. Consultant: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Avillion LLP, Boehringer Ingelheim, Eli Lilly and Company, Galderma S.A., Janssen Biotech, Inc., LEO Pharma Inc., Menlo Therapeutics Inc., Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc., Promius Pharma, LLC. Investigator: AbbVie Inc., Amgen Inc., Boehringer Ingelheim, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron. Speakers Bureau: AbbVie Inc., Amgen Inc., Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC.
Jashin J. Wu, MD, Contracted Research: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Regeneron.
University of Louisville CME & PD Advisory Board and Staff Disclosures: The CME & PD Advisory Board and Staff have nothing to disclose.
CME/CE Reviewers: Timothy S. Brown, MD, Clinical Associate Professor, Division of Dermatology, Department of Medicine, University of Louisville School of Medicine. The Postgraduate Institute of Medicine planners and managers Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Global Academy for Medical Education Staff: Suzanne Bujara; Tristan M. Nelsen, MNM, CMP, HMCC; Sylvia H. Reitman, MBA, DipEd; and Ron Schaumburg have nothing to disclose.
Off-Label/Investigational Use Disclosure
This CME/CE activity discusses the off-label use of certain approved medications as well as data from clinical trials on investigational agents. Such material is identified within the text of the articles.
This continuing medical education (CME/CE) supplement was developed from interviews with the faculty. The Guest Editors acknowledge the editorial assistance of Global Academy for Medical Education and Suzanne Bujara, medical writer, in the development of this supplement. The manuscript was reviewed and approved by the guest editors as well as the Editors of Seminars in Cutaneous Medicine and Surgery. The ideas and opinions expressed in this supplement are those of the Guest Editors and do not necessarily reflect the views of the supporter, Global Academy for Medical Education, University of Louisville, Postgraduate Institute for Medicine, or the publisher.
References
- Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. doi: 10.1038/nrdp.2016.82.
- Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: An update on developing targeted therapies. Dis Model Mech. 2012;5:423-433.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psori- asis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
- Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. J Clin Aesthet Dermatol. 2016;9(suppl 1):S3-S6.
- Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251-259.
- Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178:132-139.
- Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2:271-278.
- American Academy of Dermatology. Psoriasis clinical guideline. https://www.aad.org/ practicecenter/quality/clinical-guidelines/psoriasis. Accessed December 5, 2017.
- Taclonex (calcipotriene and betamethasone dipropionate) [prescribing information]. Madison, NJ: LEO Pharma Inc; 2017.
- Enstilar (calcipotriene and betamethasone dipropionate) [prescribing information]. Madison, NJ: LEO Pharma Inc; 2017.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114-135.
- Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcu- taneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:528-537.
- Otezla (apremilast) [prescribing information]. Summit, NJ: Celgene Corporation; 2017.
- Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2017.
- Papp KA, Tyring S, Lahfa M, et al; for the Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
- Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72:115-122.
- Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psori- asis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
- Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; 2017.
- Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008;2: 115-124.
- Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to- severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1-15.
- Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2017.
- Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
- Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.
- Stelara (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2017.
- US Food and Drug Administration. FDA approves new psoriasis drug Cosentyx [press release]. January 21, 2015. http://wayback.archive-it.org/
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.html. Accessed February 15, 2018. - Pariser D, Frankel E, Schlessinger J, et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis in the North American subgroup of patients: Pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2008;8:17-32.
- Taltz(ixekizumab)[prescribinginformation]. Indianapolis,IN:Eli Lilly and Company; 2017.
- Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) [published online October 9, 2017]. Br J Dermatol. doi:10.1111/bjd.16050.
- Siliq (brodalumab) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017.
- Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis. A review of phase III trials. Dermatol Ther (Heidelb). 2016;6:111-124.
- Tremfya (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; 2017.
- Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276-288.
- Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate- to-severe plaque psoriasis. N Engl J Med. 2017;376:1551-1560.
- Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals—A report on an implementation meeting. J Eur Acad Dermatol Venereol. 2011;25(suppl 3):1-13.
- Davison NJ, Warren RB, Mason KJ, et al. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: A prospective, multicentre cohort study. Br J Dermatol. 2017;177:828-836.
- Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290-298.
Disclosures
*Associate Professor of Clinical Dermatology, Associate Dean for Clinical Research, Keck School of Medicine of the University of Southern California, Los Angeles, California
† Professor and Chair, Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin
‡ Chairman, Division of Dermatology, Baylor University Medical Center, Dallas, Texas
§ Director of Dermatology Research, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
Publication of this CME/CE article was jointly provided by University of Louisville, Postgraduate Institute for Medicine, and Global Academy for Medical Education, LLC, and is supported by an educational grant from Ortho Dermatologics. The authors have received an honorarium for their participation in this activity. They acknowledge the editorial assistance of Suzanne Bujara, medical writer, and Global Academy for Medical Education in the development of this continuing medical education journal article.
April W. Armstrong, MD, MPH, Consultant: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Modernizing Medicine, Novartis Pharmaceuticals Corporation, Regeneron, Sanofi. Speakers Bureau: AbbVie Inc., Eli Lilly and Company, Janssen Biotech, Inc.
Kenneth B. Gordon, MD, Consultant: AbbVie Inc., Amgen Inc., Almirall, S.A., Boehringer Ingelheim, Bristol Myers-Squibb Company, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc. Investigator: AbbVie Inc., Boehringer Ingelheim, Celgene Corporation, Novartis Pharmaceuticals Corporation.
M. Alan Menter, MD, Advisory Board: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Boehringer Ingelheim, Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC. Consultant: AbbVie Inc., Afecta Pharmaceuticals, Inc., Amgen Inc., Avillion LLP, Boehringer Ingelheim, Eli Lilly and Company, Galderma S.A., Janssen Biotech, Inc., LEO Pharma Inc., Menlo Therapeutics Inc., Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc., Promius Pharma, LLC. Investigator: AbbVie Inc., Amgen Inc., Boehringer Ingelheim, Celgene Corporation, Dermira, Inc., Eli Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron. Speakers Bureau: AbbVie Inc., Amgen Inc., Janssen Biotech, Inc., LEO Pharma Inc., Ortho Dermatologics, Promius Pharma, LLC.
Jashin J. Wu, MD, Contracted Research: AbbVie Inc., Amgen Inc., Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceutical s Corporation, Regeneron.
Address reprint requests to: April W. Armstrong, MD, MPH, Office of the Dean, Keck School of Medicine, University of California, 1975 Zonal Avenue, Los Angeles, CA 90089; aprilarmstrong@post.harvard.edu